Basilea Pharmaceutica (SIX: BSLN)

Currency in CHF

Last close As at 30/03/2023

CHF49.75

0.50 (1.02%)

Market capitalisation

CHF653m

Basilea Pharmaceutica is focused on treating infectious diseases. Its marketed products are Cresemba (an antifungal) and Zevtera (an anti-MRSA broad-spectrum antibiotic). The company plans to file for US approval for Zevtera.

There is an ever-increasing need for therapeutic agents that are efficacious against drug-resistant strains of bacteria (eg MRSA) or fungi. Hence the opportunities for Cresemba and Zevtera could be significant.

misael-moreno-fN6K30xtiKE-unsplash

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Adesh Kaul

    CFO

  • David Veitch

    CEO

  • Dung Tran

    Investor relations coordinator

Balance Sheet

Forecast net cash (CHFm)

1.5

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (4.7) 7.8 31.1
Relative (3.5) 6.8 47.3
52 week high/low CHF55.2/CHF29.9

Financials

Basilea has announced that it has received a development-related milestone payment of CHF5m from its Japanese licensing partner, Asahi Kasei Pharma. This was triggered through the launch of Basilea’s flagship antifungal therapy, Cresemba, in Japan. Having been approved in 73 countries and marketed in 65, Cresemba is one of the major antifungal products on the market, capturing c 12% of global sales of best-in-class antifungals by end-2022. Japan is a key strategic territory for Basilea, representing c 4% of Cresemba’s future market potential, and the successful launch will help continue sales momentum and drive profitable growth in FY23, in our view.

Y/E Dec Revenue (CHFm) EBITDA (CHFm) PBT (CHFm) EPS (CHFc) P/E (x) P/CF (x)
2021A 148.1 1.9 (6.6) (56.90) N/A N/A
2022A 147.8 19.6 12.3 104.10 47.8 N/A
2023E 156.7 49.8 40.9 312.63 15.9 N/A
2024E 180.7 66.8 62.0 473.38 10.5 N/A

Research

Healthcare

Basilea Pharmaceutica – executive interview

Healthcare

Basilea Pharmaceutica – executive interview

Healthcare

Basilea Pharmaceutica — Momentum continues

Healthcare

Basilea Pharmaceutica – executive interview

Healthcare

Executive interview – Basilea Pharmaceutica

Healthcare

Executive interview – Basilea Pharmaceutica

Healthcare

Basilea Pharmaceutica — Strength in numbers

Healthcare

Basilea Pharmaceutica — Steady as she goes

Further insights

Healthcare

Antibiotic resistance

Healthcare

Antibiotics

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Healthcare

Drug delivery platforms

Healthcare

Neuroscience comeback

Consumer

IPO apocalypse

TMT

ESG, moving beyond the box tick

Healthcare

Artificial intelligence in drug discovery

Healthcare

Edison Exhibits- antibiotic development

Healthcare

The next wave in AMD

Healthcare

Cannabinoid Therapies- The coming retail wave

Healthcare

The diagnostics sector

Healthcare

ASCO 2017